Centessa Pharmaceuticals plc 260.F Stock
Centessa Pharmaceuticals plc Price Chart
Centessa Pharmaceuticals plc 260.F Financial and Trading Overview
Centessa Pharmaceuticals plc stock price | 7.6 EUR |
Previous Close | 4.34 EUR |
Open | 4.78 EUR |
Bid | 4.78 EUR x N/A |
Ask | 5.2 EUR x N/A |
Day's Range | 4.78 - 4.78 EUR |
52 Week Range | 2.72 - 5.55 EUR |
Volume | 45 EUR |
Avg. Volume | 0 EUR |
Market Cap | 551.22M EUR |
Beta (5Y Monthly) | 0.862676 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.46 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 38.67 EUR |
260.F Valuation Measures
Enterprise Value | 148.12M EUR |
Trailing P/E | N/A |
Forward P/E | -1.6539793 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.5499351 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.723 |
Trading Information
Centessa Pharmaceuticals plc Stock Price History
Beta (5Y Monthly) | 0.862676 |
52-Week Change | 10.63% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.55 EUR |
52 Week Low | 2.72 EUR |
50-Day Moving Average | 3.86 EUR |
200-Day Moving Average | 3.6 EUR |
260.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 95.61M |
Float | 20.11M |
Short Ratio | N/A |
% Held by Insiders | 1.85% |
% Held by Institutions | 77.04% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -25.97% |
Return on Equity (ttm) | -54.93% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -204782000 EUR |
Net Income Avi to Common (ttm) | -212423008 EUR |
Diluted EPS (ttm) | -2.1 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 346.23M EUR |
Total Cash Per Share (mrq) | 3.64 EUR |
Total Debt (mrq) | 81.31M EUR |
Total Debt/Equity (mrq) | 27.73 EUR |
Current Ratio (mrq) | 12.947 |
Book Value Per Share (mrq) | 3.084 |
Cash Flow Statement
Operating Cash Flow (ttm) | -198367008 EUR |
Levered Free Cash Flow (ttm) | -106633000 EUR |
Profile of Centessa Pharmaceuticals plc
Country | Germany |
State | N/A |
City | Altrincham |
Address | 1 Ashley Road |
ZIP | WA14 2DT |
Phone | 44 203 9206789 |
Website | https://www.centessa.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 82 |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Q&A For Centessa Pharmaceuticals plc Stock
What is a current 260.F stock price?
Centessa Pharmaceuticals plc 260.F stock price today per share is 7.6 EUR.
How to purchase Centessa Pharmaceuticals plc stock?
You can buy 260.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Centessa Pharmaceuticals plc?
The stock symbol or ticker of Centessa Pharmaceuticals plc is 260.F.
Which industry does the Centessa Pharmaceuticals plc company belong to?
The Centessa Pharmaceuticals plc industry is Biotechnology.
How many shares does Centessa Pharmaceuticals plc have in circulation?
The max supply of Centessa Pharmaceuticals plc shares is 114.77M.
What is Centessa Pharmaceuticals plc Price to Earnings Ratio (PE Ratio)?
Centessa Pharmaceuticals plc PE Ratio is now.
What was Centessa Pharmaceuticals plc earnings per share over the trailing 12 months (TTM)?
Centessa Pharmaceuticals plc EPS is -1.46 EUR over the trailing 12 months.
Which sector does the Centessa Pharmaceuticals plc company belong to?
The Centessa Pharmaceuticals plc sector is Healthcare.